Beyond Pieris' fully proprietary pipeline, more than ten Anticalin-based therapeutic programs are currently being advanced under partnership collaborations, many of which Pieris retains co-development and co-commercialization rights or full USA development and commercialization rights. Armed with positive human data and validated through selected partnerships, the Anticalin technology is one of the most mature next generation therapeutic protein technologies available for partnering today. Pieris is open to discuss partnering opportunities in the following areas:
For its Anemia program, PRS-080 (anti-Hepcidin Anticalin), a first partnership has been signed in certain Asian territories in 2017. As part of its ongoing transformation into an immunology-focused company, Pieris will seek partnerships in the US and EU for PRS-080 following the completion of an ongoing Phase IIa trial in dialysis-dependent anemia patients.
Pieris is open to discuss additional partnerships that deploy the Anticalin platform in high-value therapeutic areas.